US_AEHR 2024-08-30 Q1

Status: OK — incomplete — unset metrics listed below; Currency: USD; Amounts unit: millions; Forms: ✓ ✓ ✓

To recalculate statement detection and previews from the PDF, use this link The default link runs in the background: a status panel shows phase, elapsed time, rough ETA, CUDA vs CPU, and OOM hints, then loads the finished report. Heavy mode with refresh does this automatically so reverse proxies do not return 502. Add &sync=1 only for one long blocking request (not recommended). You can use ?refresh=1, ?recalc=1, ?nocache=1, or ?recompute=1 on the URL. (block in the browser until done: synchronous refresh)

Default view is fast (metric table + statement page numbers only) so reverse proxies do not time out. Use ?heavy=1 when you need embedded page images and Camelot tables.

Metric mapping (value → extracted evidence)

Metric values use dashboard units where applicable; evidence is the stored snippet from the PDF text layer or OCR used during extraction.

Structured statements (SEC US-GAAP)

Metric	Value	Evidence / page extract
Revenue	13.12	—
Operating profit	0.159	—
D&A	0.347	Row: derived: same-row components · dashboard=0.347 mln — derived: same-row components
EBITDA	0.506	—
Net profit	0.66	—
Cash	37.83	—
Debt short	0.827	—
Debt long	—	—
Net debt	-37	Components: short debt 0.827 + long debt 0 + other financial liab. 0 + NCI 0 − cash 37.83 = net debt -37.Row: debt_short + debt_long + other_financial_liabilities + non_controlling_interest − cash (from row components) · dashboard=-37.003 mln — debt_short + debt_long + other_financial_liabilities + non_controlling_interest − cash (from row components)
Operating CF	2.38	—
Investing CF	-10.81	—
Assets	145.86	—
Equity	122.48	—

P&L (US-GAAP, duration)

Line item	XBRL tag	Value (USD mln)
Revenue	`Revenues`	13.12
Cost of revenue	`CostOfRevenue`	6.041
Gross profit	`GrossProfit`	7.078
Operating expenses	`OperatingExpenses`	6.919
Research and development	`ResearchAndDevelopmentExpense`	2.361
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	4.558
Operating income (loss)	`OperatingIncomeLoss`	0.159
Income tax expense (benefit)	`IncomeTaxExpenseBenefit`	0.154
Net income (loss)	`NetIncomeLoss`	0.66
Depreciation & amortization	`DepreciationAndAmortization`	0.347
EBITDA (OP + D&A)	`OperatingIncomeLoss+DepreciationDepletionAndAmortization`	0.506

Balance sheet (US-GAAP, point in time)

Line item	XBRL tag	Value (USD mln)
Total assets	`Assets`	145.86
Cash and equivalents	`CashAndCashEquivalentsAtCarryingValue`	37.83
Receivables (net)	`AccountsReceivableNet`	8.561
Inventory (net)	`InventoryNet`	42.97
PP&E (net)	`PropertyPlantAndEquipmentNet`	3.503
Goodwill	`Goodwill`	10.35
Total liabilities	`Liabilities`	23.38
Stockholders' equity	`StockholdersEquity`	122.48
Current / short-term debt (sum of tags)	`DebtCurrent+…`	0.827

Cash flow (US-GAAP, duration)

Line item	XBRL tag	Value (USD mln)
Operating cash flow	`NetCashProvidedByUsedInOperatingActivities`	2.38
Investing cash flow	`NetCashProvidedByUsedInInvestingActivities`	-10.81
Financing cash flow	`NetCashProvidedByUsedInFinancingActivities`	-0.106
Capex (PP&E purchases)	`PaymentsToAcquirePropertyPlantAndEquipment`	0.197

Source: data.sec.gov company facts. Quarterly cash-flow lines use the same incremental YTD logic as dashboard totals. Not all filers tag every line; tags are US-GAAP labels from the API.

Statement pages (discovery)

Statement previews & reconstructed tables

Page previews unavailable (missing PDF, no discovery pages, or PDF renderer not available).

✓	Balance sheet identity (A = L + E)	Implied total liabilities (TA − TE) = 23; known debt components fit within that envelope.
✓	Net debt formula	net_debt -37 matches \|debt_short\|+\|debt_long\|+\|other\|+\|NCI\|−\|cash\| = -37.
✓	EBITDA = OP + D&A	EBITDA (1) ≈ OP (0) + D&A (0) = 1.
⚠	Net profit vs operating profit	Net profit (1) > 1.5× operating profit (0) — implies a large non-operating gain (asset disposal, FX, one-off). Check the column mapping if no such item is reported.
✓	Cash ≤ total assets	Cash (38) ≤ total assets (146).

US_AEHR 2024-08-30 Q1 — report review